Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2001 March; 2(1): 11–22.
Published online 2001 January 11. doi:  10.1208/pt020101
PMCID: PMC2750255

Statistical optimization of gastric floating system for oral controlled delivery of calcium


The development of an optimized gastric floating drug delivery system is described. Statistical experimental design and data analysis using response surface methodology is also illustrated. A central, composite Box-Wilson design for the controlled release of calcium was used with 3 formulation variables: X1 (hydroxypropyl methylcellulose [HPMC] loading), X2 (citric acid loading), and X3 (magnesium stearate loading). Twenty formulations were prepared, and dissolution studies and floating kinetics were performed on these formulations. The dissolution data obtained were then fitted to the Power Law, and floating profiles were analyzed. Diffusion exponents obtained by Power Law were used as targeted response variables, and the constraints were placed on other response variables. All 3 formulation variables were found to be significant for the release properties (P<,05), while only HPMC loading was found to be significant for floating properties. Optimization of the formulations was achieved by applying the constrained optimization. The optimized formulation delivered calcium at the release rate of 40 mg/hr, with predicted n and T50% values at 0.93 and 3.29 hours, respectively. Experimentally, calcium was observed to release from the optimized formulation with n and T50% values of 0.89 (±0.10) and 3.20 (±0.21) hours, which showed an excellent agreement. The quadratic mathematical model developed could be used to further predict formulations with desirable release and floating properties.

Key Words: Calcium, Gastric floating system, Oral controlled delivery, Statistical optimization, Response surface methodology (RSM)

Full Text

The Full Text of this article is available as a PDF (393K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst. 1993;10(2):143–159. [PubMed]
2. Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci. 1994;83(Feb):239–245. doi: 10.1002/jps.2600830225. [PubMed] [Cross Ref]
3. Jimenez Castellanos MR, Zia H, Rhodes CT. Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm. 1994;105:65–70. doi: 10.1016/0378-5173(94)90236-4. [Cross Ref]
4. Watanabe K. Preparation and evaluation of intragastric floating tablet having pH independent buoyancy and sustained release property. Arch Pract Pharm Yakuzaigaku. 1993;53:1–7.
5. Desai S, Bolton S. Floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm Res. 1993;10(Sep):1321–1325. doi: 10.1023/A:1018921830385. [PubMed] [Cross Ref]
6. Thanoo AC, Sunny MC, Jayakrishnan A. Oral sustained-release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluid. J Pharm Pharmacol. 1993;45(Jan):21–24. [PubMed]
7. Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxicillin trihydrate. Int J Pharm. 1992;86(10):79–88. doi: 10.1016/0378-5173(92)90033-X. [Cross Ref]
8. Xu WL, Tu XD, Lu ZD. Development of gentamicin sulfate sustained-release tablets remaining-floating in stomach. Yao Hsueh Hsueh Pao. 1991;26(7):541–545. [PubMed]
9. Gerogiannis VS, Rekkas DM, Dallas PP, Choulis NH. Floating and swelling characteristics of various excipients used in controlled release technology. Drug Dev Ind Pharm. 1993;19(9):1061–1081. doi: 10.3109/03639049309063001. [Cross Ref]
10. Chueh HR, Zia H, Rhodes CT. Optimization of sotalol floating and bioadhesive extended release tablet formulations. Drug Dev Ind Pharm. 1995;21(15):1725–1747. doi: 10.3109/03639049509069261. [Cross Ref]
11. Heaney RP. Calcium bioavailability. Bol Asoc Med P R. 1987;79(1):27–29. [PubMed]
12. Allen LH. Calcium bioavailability and absorption: a review. Am J Clin Nutr. 1982;35(4):783–808. [PubMed]
13. Pak AY, Harvey JA, Hsu MC. Enhanced calcium bioavailability from a solubilized form of calcium citrate. J Clin Endocrinol Metab. 1987;65(4):801–805. doi: 10.1210/jcem-65-4-801. [PubMed] [Cross Ref]
14. Pointillart A, Gueguen L. Meal-feeding and phosphorus ingestion influence calcium bioavailability evaluated by calcium balance and bone breaking strength in pigs. Bone Miner. 1993;21(1):75–81. doi: 10.1016/S0169-6009(08)80122-5. [PubMed] [Cross Ref]
15. Nickel K. P. Calcium bioavailability from bovine milk and dairy products in premenopausal women using intrinsic and extrinsic labeling techniques. J Nutr. 2001;126(5):1406–1411. [PubMed]
16. Box GEP, Wilson KB. On the experimental attainment of optimum conditions. J Roy Statist Soc. 1951;13(B):1–1.
17. Fonner AE, Buck JR, Banker GS. Mathematical optimization techniques in drug product design and process analysis. J Pharm Sci. 1970;59(11):1587–1596. doi: 10.1002/jps.2600591110. [PubMed] [Cross Ref]
18. Franz RM, Sytsma JA, Smith BP, Lucisano LJ. In vitro evaluation of a mixed polymeric sustained relase matrix using response surface methodology. J Control Release. 1987;5(Sep):59–172.
19. Timmermans J, Moes AJ. Measuring the resultantweight of an immersed test material: I. Validation of an apparatus and a method dedicated to pharmaceutical applications. Acta Pharm Technol. 1990;36(3):171–175.
20. Colombo P, Bettini R, Santi P, De Ascentiis A, Peppas NA. Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport. J Control Release. 2001;39(May):231–237.
21. Mallow A. L. Some comments on Cp. Technometrics. 1999;15:661–675. doi: 10.2307/1267380. [Cross Ref]
22. Murray J. X-STAT Menu. 1992.
23. Schwartz JB, Flamholz JR, Press RH. Computer optimization of pharmaceutical formulations I: General Procedure. J Pharm Sci. 1973;62(7):1165–1170. doi: 10.1002/jps.2600620722. [PubMed] [Cross Ref]
24. Timmermans J, Moes AJ. Cutoff size for gastric emptying of dosage forms. J Pharm Sci. 1993;82(Aug):854–854. doi: 10.1002/jps.2600820821. [PubMed] [Cross Ref]
25. Oth M, Franz M, Timmermans J, Moes A. The bilayer floating capsule: a stomach-directed drug delivery system for misoprostol. Pharm Res. 1992;9(3):298–302. doi: 10.1023/A:1015870314340. [PubMed] [Cross Ref]
26. Ichikawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage system. I: Preparation and in vitro evaluation of floating and sustainedreleased characteristics. J Pharm Sci. 2001;80(11):1062–1066. doi: 10.1002/jps.2600801113. [PubMed] [Cross Ref]
27. Timmermans J, Moes AJ. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J Pharm Sci. 1994;83(Jan):18–24. doi: 10.1002/jps.2600830106. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists